Unstable Angina
Conditions
Keywords
unstable angina, drug therapy, myocardial ischemia, myocardial infarction, hemorrhage
Brief summary
The purpose of this study is to determine whether enoxaparin (an anticoagulant) is effective in the treatment of patients presenting to the emergency room with chest pain and no electrocardiogram or bloodwork evidence of a heart attack, but with other high risk clinical features
Detailed description
Patients with chest pain and abnormal electrocardiogram or bloodwork (biomarker) indicative of a heart attack benefit from anticoagulant therapy such as enoxaparin. However, even patients without abnormalities on the electrocardiogram or bloodwork are at increased risk for heart attack or death, if they have certain clinical risk factors. It is currently not known whether enoxaparin is also beneficial for these patients. Comparison: enoxaparin in addition to optimal standard care at the discretion of the treating physician, versus optimal standard care without enoxaparin
Interventions
DRUGenoxaparin
Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
Sponsors
Sanofi
Canadian Heart Research Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female (negative pregnancy test required for females of childbearing potential) ≥ 18 years of age and capable of signing informed consent; * Typical chest discomfort at rest; lasting at least 5 minutes in the prior 24 hours that is highly suggestive of myocardial ischemia and is not explained by trauma or obvious abnormalities on chest x-ray; * Two or more of high-risk clinical features.
Exclusion criteria
* Clear indication for low molecular weight or unfractionated heparin; * Pregnancy; * Increased bleeding risk; * Impaired hemostasis; * Angina from a secondary cause; * Inability to commence ST segment monitoring within 4 hours of study drug initiation; * Uninterpretable ST segment based upon baseline 12-lead ECG; * Any contraindications to treatment with LMWH (or unfractionated heparin), including heparin induced thrombocytopenia, known allergy to heparin, low molecular weight heparin, pork or pork products; * Renal insufficiency or renal dialysis; * A prosthetic heart valve; * Any other clinically relevant serious diseases; * Current evidence of inebriation with alcohol or intoxication resulting from other drug abuse; * Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or has previously enrolled in this trial; * Inability to comply with the protocol; * Inability to understand the nature, scope, and possible consequences of the study or is otherwise unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of, and time to, the composite endpoint of death, nonfatal MI, recurrent myocardial ischemia, or need for coronary revascularization | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of, and time to, the composite endpoint of death, nonfatal MI, recurrent myocardial ischemia, or need for coronary revascularization | 6 months |
| The incidence of myocardial necrosis (as detected by elevated cardiac troponin I or T). | 24 hours |
| The incidence of major (including non-CABG-related) and minor hemorrhage. | 48 hours and 30 days |
| The incidence of all-cause mortality, nonfatal MI, and the combination. | 30 and 180 days |
| One or more of the followings: hemodynamic instability, congestive heart failure, Clinical need for antithrombotic/antiplatelet therapy beyond aspirin, identifiable culprit lesion on diagnostic coronary angiography | during index hospitalization |
Countries
Canada
Outcome results
None listed